Trial · NCT04305327
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Psoriasis Area and Severity Index (PASI) 75 Response, Assessed at Week 12. | Brodalumab | NA | Participants | ||
| Psoriasis Area and Severity Index (PASI) 75 Response, Assessed at Week 12. | Placebo/Ustekinumab | NA | Participants | ||
| PASI 90 Response, Assessed at Week 12. | Brodalumab | NA | Participants | ||
| PASI 90 Response, Assessed at Week 12. | Placebo/Ustekinumab | NA | Participants | ||
| PASI 100 Response, Assessed at Week 12. | Brodalumab | NA | Participants | ||
| PASI 100 Response, Assessed at Week 12. | Placebo/Ustekinumab | NA | Participants | ||
| Overall Number of Adverse Events (AEs) | Brodalumab | Any AEs | 4 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Ustekinumab | Any AEs | 5 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Placebo/Brodalumab | Any AEs | 0 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Placebo/Ustekinumab | Any AEs | 3 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Brodalumab | Any AEs related to IMP | 0 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Ustekinumab | Any AEs related to IMP | 3 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Placebo/Brodalumab | Any AEs related to IMP | 0 | Adverse events | |
| Overall Number of Adverse Events (AEs) | Placebo/Ustekinumab | Any AEs related to IMP | 0 | Adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04305327/results